<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC89732</article-id><article-id pub-id-type="pmcid-ver">PMC89732.1</article-id><article-id pub-id-type="pmcaid">89732</article-id><article-id pub-id-type="pmcaiid">89732</article-id><article-id pub-id-type="pmid">10681324</article-id><article-id pub-id-type="doi">10.1128/aac.44.3.598-601.2000</article-id><article-id pub-id-type="publisher-id">0896</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Experimental Therapeutics</subject></subj-group></article-categories><title-group><article-title>Activities of Trovafloxacin, Gatifloxacin, Clinafloxacin, Sparfloxacin, Levofloxacin, and Ciprofloxacin against Penicillin-Resistant <italic>Streptococcus pneumoniae</italic> in an In Vitro Infection Model</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hershberger</surname><given-names initials="E">Ellie</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rybak</surname><given-names initials="MJ">Michael J.</given-names></name><xref ref-type="author-notes" rid="FN150">*</xref></contrib></contrib-group><aff id="N0x993a9f0.0x9da30b0">Anti-Infective Research Laboratory, Wayne State University, and Department of Pharmacy Services, Detroit Receiving Hospital and University Health Center, Detroit, Michigan 48201</aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: Anti-Infective Research Laboratory, Department of Pharmacy Services, Detroit Receiving Hospital and University Health Center, 4201 St. Antoine Blvd., Detroit, MI 48201. Phone: (313) 745-4554. Fax: (313) 993-2522. E-mail: <email>mrybak@dmc.org</email>.</p></fn></author-notes><pub-date pub-type="ppub"><month>3</month><year>2000</year></pub-date><volume>44</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">2482</issue-id><fpage>598</fpage><lpage>601</lpage><history><date date-type="received"><day>6</day><month>11</month><year>1998</year></date><date date-type="rev-request"><day>12</day><month>8</month><year>1999</year></date><date date-type="accepted"><day>1</day><month>12</month><year>1999</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-25 20:25:31.930"><day>25</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac000598.pdf"/><abstract><p>We adapted an in vitro pharmacodynamic model of infection to incorporate infected fibrin clots. The bactericidal activities of various fluoroquinolones against two strains of penicillin-resistant <italic>Streptococcus pneumoniae</italic> were studied over a 48-h period. Bacteria were prepared in Muller-Hinton broth by using colonies from a 24-h tryptic soy agar plus 5% sheep blood plate and were added to a mixture of cryoprecipitate (80%) and thrombin (10%) to achieve approximately 10<sup>6</sup> CFU of organism per fibrin clot. The fibrin clots were suspended into the models and removed, in triplicate, at various time points over 48 h. Control models were also conducted to characterize the growth of <italic>S. pneumoniae</italic> in the growth medium without antibiotic. Trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin were administered to simulate their pharmacokinetic profiles in humans. Fibrin clot samples were also plated onto antibiotic-containing tryptic soy agar plus 5% lysed horse blood to detect resistance. The newer fluoroquinolones demonstrated better activity than ciprofloxacin against both isolates. In conclusion, the newer quinolones demonstrated significant activity against penicillin-resistant <italic>S. pneumoniae</italic>, with standard dosing resulting in area under the concentration-time curve/MIC ratios and peak concentration/MIC ratios that resulted in 99.9% killing against these isolates.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>